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HexokinaseMetabolic oxidative stress via CYP2E1 can act as a second hit in NASH progression. Our previous studies have
shown that oxidative stress in NASH causes higher leptin levels and induces purinergic receptor X7 (P2X7r).
We tested the hypothesis that higher circulating leptin due to CYP2E1-mediated oxidative stress induces P2X7r.
P2X7r in turn activates stellate cells and causes increased proliferation via modulating Glut4, the glucose trans-
porter, and increased intracellular glucose. Using a high fat diet-fed NAFLDmodel where bromodichloromethane
(BDCM) was administered to induce CYP2E1-mediated oxidative stress, we show that P2X7r expression and pro-
tein levels were leptin and CYP2E1 dependent. P2X7r KO mice had signiﬁcantly decreased stellate cell prolifera-
tion. Human NASH livers showed marked increase in P2X7r, and Glut4 in α-SMA positive cells. NASH livers had
signiﬁcant increase in Glut4 protein and phosphorylated AKT, needed for Glut4 translocation while leptin KO
and P2X7r KO mice showed marked decrease in Glut4 levels primarily in stellate cells. Mechanistically stellate
cells showed increase in phosphorylated AKT, Glut4 protein and localization in themembrane following adminis-
tration of P2X7r agonist or leptin+ P2X7r agonist, while use of P2X7r antagonist or AKT inhibitor attenuated the
response suggesting that leptin–P2X7r axis in concert but not leptin alone is responsible for the Glut4 induction
and translocation. Finally P2X7r-agonist and leptin caused an increase in intracellular glucose and consumption
by increasing the activity of hexokinase. In conclusion, the study shows a novel role of leptin-induced P2X7r in
modulating Glut4 induction and translocation in hepatic stellate cells, that are key to NASH progression.
© Elsevier B.V. All rights reserved.20151. Introduction
There has been a recent emphasis on the role of CYP2E1 in the devel-
opment of nonalcoholic steatohepatitis, a progressive liver disease aris-
ing from a pronounced obese phenotype and a fatty liver [1–5]. CYP2E1
has been found to generatemetabolic oxidative stress, a known “second
hit” for the progression of NASH from benign steatosis [6]. Interestingly,
steatosis has been shown to be protective but a series of concomitant
conditions like formation of free radicals, oxidative stress drivenbfamily E, polypeptide 1; NASH,
X7; GLUT4, glucose transporter
NAFLD, nonalcoholic fatty liver
α-SMA, alpha smooth muscle
se; AKT, protein kinase B; ATP,
kinase.
isease Laboratory, Department
olina, Columbia, SC 29208, USA.
.
equally.cytokine increase drives an inﬂammatory phenotype in the fatty liver
[7–10]. NASH is characterized by severe metabolic disturbances that in-
clude hepatic insulin resistance, higher leptin, glucose intolerance and
disturbances in lipid metabolism [11–13]. NASH also is often associated
with ﬁbrotic phenotype due to increased proliferation and altered
morphology of stellate cells [14,15]. Stellate cells that are residents of
the “space of Disse” are specialized cells for fat storage and lose their
stored lipids to obtain a ﬁbroblastic lineage during the progression of
NASH [16].
Hepatic insulin resistance is a common occurrence in NASH and in-
sulin signaling is defective inmost cell types in the liver [17,18]. Though
liver insulin resistance is common, stellate cells have been shown to uti-
lize glucose rapidly during their proliferative phase [19,20]. The lack of
insulin signaling ormechanisms of selective insulin response in the stel-
late cells has been unclear. Though selective insulin signaling has been
shown to be preserved in adipocytes by the way of differential re-
sponses of GLUT4 translocation and lipogenesis via nuclear expulsion
of FoxO1, alternative routes of mediators of GLUT4 translocation has
been unknown [21]. Insulin effects onGLUT4 translocation has been pri-
marily found to be AKT phosphorylation mediated while defects of the
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utilization in the adipocytes [21]. There is a signiﬁcant knowledge gap in
understanding alternative signaling mediators in mediating GLUT4
translocation, induction and increased intracellular glucose transport
especially in NASH.
Leptin resistance is common in human NASH [22]. We and others
have shown that CYP2E1-derived oxidative stress increases leptin levels
in the liver, induces NADPH oxidase derived protein free radicals [23,
24]. Leptin also has been shown to be a key driver of stellate cell activa-
tion, proliferation andﬁbrosis inNASH [25,26]. Leptin is also responsible
in GLUT4 translocation and glucose uptake in stellate cells and cells of
neuronal origin though the exact pathways and molecular mediators
of its function are largely elusive [19,27]. Our recent laboratory observa-
tions coupled with several other reports of the role of purinergic recep-
tors, in causingKupffer cell activation, autophagy andNASHprogression
have thrown important light on the role of these innate immune medi-
ators in NASH [28–31]. P2X7 receptors are ion channels responsive to
high concentrations of ATP that is released following cellular necrosis
[31,32]. P2X7 receptors upon activation are known to perform several
important cellular tasks including caspase-1 dependent IL1β production
and in lipid metabolism [31,33]. The P2X7 receptor (P2X7r) is one such
multifunctional protein that is related tomultiple partners and signaling
pathways [34]. The P2X7r–lipidmetabolism pathway is related tomany
biological functions of P2X7R, such as cell death and pathogen clearance
[35]. This signaling pathwaymay be involved inmany functions that are
dependent on bioactive lipids, activation of the different cellular signal-
ing pathways that maymimic insulin signaling and provide an explana-
tion to the differential behavior of stellate cell glucose transport and
proliferative responses even in a state of profound insulin resistance
[36].
In this studywehypothesize that CYP2E1 driven oxidative stress and
increased leptin results in P2X7r induction and concomitant activation
leading to AKT pathway activation. The increased phosphorylation of
AKT leads to GLUT4 translocation to the stellate cell membranes
resulting in increased intracellular glucose and stellate cell activation
in NASH. We use a diet induced obese mouse model to have a fatty
liver phenotype (simple steatosis) with no inﬂammation or ﬁbrosis
(NAFLD group) [37]. CYP2E1 mediated oxidative stress is generated by
administering a hepatotoxin bromodichloromethane (BDCM). We
chose to use the steatosis stage of NAFLDwith no inﬂammation or ﬁbro-
sis to demonstrate the effect of metabolic oxidative stress and its
consequences.
Our results from both in-vivo (mouse model of NAFLD) and in-vitro
models (rat stellate cells) show that increased leptin due to CYP2E1 de-
rived oxidative stress induce P2X7r and activates it resulting in in-
creased GLUT4 protein levels in stellate cells. The GLUT4 translocation
is also increased in these cells following co-incubation with P2X7r ago-
nist and is mediated by AKT phosphorylation. The above mechanisms
suggested that leptin induced P2X7r activation might be key to the glu-
cose utilization and high energy demand for proliferating stellate cells.
2. Materials and methods
2.1. Mice model for NAFLD
Pathogen-free, adult, male mice with C57BL/6J background (Jackson
Laboratories, Bar Harbor, ME) were used in the study. They were fed
with a high-fat diet (60% kcal fat) from 6 weeks to 16 weeks and used
as a model of nonalcoholic fatty liver disease (NAFLD). All experiments
were conducted at the completion of 16 weeks. The animals were
housed one in each cage before any experimental use. Mice that
contained the deleted purinergic receptor X7 gene (P2X7r KO)
(B6.129P2-P2rx7tm1Gab/J) and mice that contained the disrupted OB
gene (leptin) (B6.V-LepbobN/J) (Lep KO) were purchased from Jackson
Laboratories. All groups of mice were fed with a high-fat diet and treat-
ed identically to NAFLDmice. All groups ofmice had ad libitum access tofood and water and were housed in a temperature-controlled room at
23–24 °C with a 12-h:12-h light/dark cycle. All animals were treated
in strict accordance with the NIH Guide for the Humane Care and Use
of Laboratory Animals, and the experimentswere approved by the insti-
tutional review boards at NIEHS, Duke University, and the University of
South Carolina at Columbia. The high fat diet was procured from
Research Diet Inc., USA.
2.2. Induction of liver injury
NAFLDmice or high-fat diet fed gene speciﬁc knockout mice (P2X7r
KO and Lep KO) were administered with bromodichloromethane
(BDCM) (1.0 mmol/kg, diluted in olive oil) through the intraperitoneal
route twice a week for 4 weeks to assess the effects of chronic exposure
of BDCM (NAFLD + BDCM, P2X7r KO and Lep KO). However, NAFLD
mice treated with olive oil (diluent of BDCM) were used as control
(NAFLD). After completion of the treatment, mice of all study groups
were sacriﬁced for liver tissue and serum for the further experiments.
2.3. Inhibition of CYP2E1 by diallyl sulﬁde
A set of high-fat diet fed, BDCM treatedmice (NAFLD+BDCM)were
administeredwith 50mg/kgdiallyl sulﬁde (diluted in corn oil) via intra-
peritoneal injection, twice a week for 4 weeks. This group of mice was
referred as DAS.
2.4. Laboratory analysis
2.4.1. Immunohistochemistry
Formalin-ﬁxed, parafﬁn-embedded liver tissue from all the mice
groups were cut into 5 μm thick tissue sections. Each section was
deparafﬁnized using standard protocol. Brieﬂy, sectionswere incubated
with xylene twice for 3 min, washed with xylene:ethanol (1:1) for
3 min, and rehydrated through a series of ethanol (twice with 100%,
95%, 70%, 50%), twice with distilled water, and ﬁnally rinsed twice
with PBS (Sigma-Aldrich). Epitope retrieval of deparafﬁnized sections
was carried out using epitope retrieval solution and steamer (IHC-
World,Woodstock,MD) following themanufacturer's protocol. The pri-
mary antibodies anti-P2X7r, anti-α-SMA and anti-GLUT4 were pur-
chased from Abcam (Cambridge, MA) and used in 1:250 dilutions.
Antigen-speciﬁc immunohistochemistry were performed using
Vectastain Elite ABC kit (Vector Laboratories, Burlingame, CA) following
manufacturer's protocols. 3,3′-Diaminobenzidine (Sigma-Aldrich) was
used as a chromogen substrate. Sections were counter-stained by
Mayer's hematoxylin (Sigma-Aldrich). A double stain IHC was per-
formed for dual labeling of GLUT4 and α SMA using the MULTIVIEW®
(mouse-HRP/mouse-AP) IHC kit from Enzo life Sciences (Farmingdale,
NY). The sections were deparafﬁnized as described above and staining
was performed according to the manufacturer's instructions. Washing
with PBS (Sigma-Aldrich)was performed thrice between the steps. Sec-
tions were mounted in simpo mount (GBI Laboratories, Mukilteo, WA)
and observed under a 20× oil objective. Morphometric analysis was
done using CellSens Software from Olympus America.
2.4.2. Quantitative RT-PCR
Gene expression levels in tissue samples were measured by two-
step qRT-PCR. Total RNA was isolated from liver tissue and cells grown
in a monolayer by homogenization in TRIzol reagent (Invitrogen) ac-
cording to the manufacturer's instructions and puriﬁed with the use of
RNeasy mini kit columns (Qiagen, Valencia, CA). Puriﬁed RNA (1 μg)
was converted to cDNA using iScript cDNA synthesis kit (Bio-Rad) fol-
lowing the manufacturer's standard protocol. qRT-PCR was performed
with the gene-speciﬁc primers using SsoAdvanced SYBR Green
supermix (Bio-Rad) and CFX96 thermal cycler (Bio-Rad). Threshold
Cycle (Ct) values for the selected genes were normalized against 18S
(internal control) values in the same sample. Each reaction was carried
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liver sample was used as the control for comparison with all other liver
samples form study groups of mice. The relative fold change was calcu-
lated by the 2−ΔΔCt method. The sequences for the primers used for
real-time PCR are provided in Suppl Table 1.
2.4.3. Western blotting
Tissue (30 mg) from each liver sample was homogenized in
500 μl of RIPA buffer (Sigma-Aldrich) with protease inhibitor
(1×) (Pierce, Rockford, IL) using dounce homogenizer. For cells
growing in monolayer were harvested using 0.05% Trypsin–EDTA
(Gibco) and lysed in MPER lysis buffer (100 μl) (Thermo-Scientif-
ic). The lysate was sonicated using the Branson ultrasound
sonicator. The homogenate was centrifuged and supernatant used
for SDS PAGE Western blotting. 30 μg of protein from each sampleFig. 1. A (i–iv). P2X7r immunoreactivity as shown by immunohistochemistry in liver slices fro
(NAFLD), NAFLD mice exposed to bromodichloromethane (BDCM) referred as NAFLD + BD
(DAS) and themice deﬁcient of leptin gene fed with high-fat diet and exposed to BDCM (Lep K
reactivity (mean data from three separate microscopic ﬁeldswere plotted on Y-axis in NAFLD, N
in liver tissue of NAFLD, NAFLD+BDCM, DAS and Lep KO groups of mice as assessed by quantita
group and represented as fold changes to NAFLD (*P b 0.05).was loaded on Novex (Invitrogen, Carlsbad, CA) 4–12% bis–tris gra-
dient gel and run for completion of SDS PAGE. Resolved proteins
bands were transferred to nitrocellulose membrane using precut
nitrocellulose/ﬁlter paper sandwiches (Bio-Rad Laboratories,
Hercules, CA) and Trans-Blot Turbo transfer system (Bio-Rad) in
case of low molecular weight proteins and using wet transfer mod-
ule from Invitrogen in case of high molecular weight proteins. A so-
lution of 5% non-fat milk was used for blocking. Primary antibodies
against α-SMA, GLUT4, p-AKT and β-actin, Total AKT (all were pur-
chased from Abcam), at recommended dilutions, and compatible
horseradish peroxidase-conjugated secondary antibodies were
used. Pierce ECL Western blotting substrate (Thermo Fisher Scientiﬁc,
Rockford, IL) was used. The blot was imaged using G:Box Chemi XX6
(Syngene imaging systems) and subjected to densitometry analysis
using Image J.mmice fed with high-fat diet (60% kcal fat) as a model of nonalcoholic fatty liver disease
CM, NAFLD mice co-exposed with BDCM and Diallyl sulﬁde, a known CYP2E1 inhibitor
O). Images were taken at 20× magniﬁcation. B. Morphometric analysis of P2X7r immuno-
AFLD+ BDCM, DAS and Lep KO groups ofmice (*P b 0.05). C. mRNA expressions of P2X7r
tive real time PCR, the expressionswere normalizedwith 18S and compared to theNAFLD
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Immortalized rat hepatic stellate cell line (8B) kindly provided to us
by Dr. Anna Mae Diehl (Duke-Gastroenterology), were maintained in
high glucose Dulbecco's modiﬁed eagles medium (DMEM), Corning
(Tewksbury, MA) supplemented with 10% fetal bovine serum (FBS), At-
lanta biologicals (Norcross, GA) supplemented with 2 mM glutamine,
100 U/ml penicillin, and 100 μg/ml streptomycin; Gibco (Grand Island,
NY) at 37 °C in a humidiﬁed atmosphere of 5% CO2. The cells were
then treated with leptin 100 ng/ml, Biovision (Milpitas, CA) (Lep), Ben-
zoyl ATP as P2X7r agonist (P7 Ag), 50 μM P13K inhibitor (LY294002)
(AKTi) and 100 μM P2X7r antagonist (A438079) (P7 An), separately
or in combination with leptin and Benzoyl ATP (Lep + P7 Ag), leptin
and A438079 (Lep+ P7 An), leptin and LY294002 (Lep + AKTi), leptin
and Benzoyl ATP and LY294002 (Lep + P7 Ag + AKTi) for 48 h and
processed for future experiments. The inhibitors and agonist were pur-
chased from Santa Cruz Biotechnology (Dallas, TX). Freshly isolated rat
hepatocytes (TRL, Research Triangle Park, NC)were incubatedwithhigh
glucose DMEM media supplemented with 10% FBS and exposed to
100 μM BDCM for 48 h at 37 °C in a humidiﬁed atmosphere of 5% CO2.
The cells were harvested and supernatant were used as a conditioned
media for hepatic stellate cells. 8B cells were incubated with 1:5 fold di-
luted conditioned media (CM) alone or in combination with LY294002
(CM+ AKTi) for 48 h and cells were used for further experiments.
2.4.5. Immunoﬂuorescence
Treated and control 8B cells were ﬁxed in 10% Neutral buffered For-
malin for 15 min at room temperature (RT). They were then
permeablized in PBS with 0.1% Triton X (PBSTx) for 10 min followed
by blocking with PBS containing 10% fetal bovine serum, 3% bovine
serum albumin and 0.2% Tween 20 for 1 h, then incubated with primary
antibodies GLUT4 and p-AKT (1:1000) diluted in blocking buffer at 4 °C
overnight. Cells were washed thrice in PBSTx for 10 min each. The cells
were then incubated with compatible AlexaFlour conjugated secondary
antibodies 633 (red) for GLUT4 and 488 (green) for p-AKT from
Invitrogen (Grand Island, NY), followed by three washes in PBSTx for
10min each. Finally, the cellsweremounted in Prolong gold antifade re-
agent with DAPI. Images were taken under 40× objective using the
Olympus BX51 microscope.
2.4.6. Biochemical assays for intracellular glucose and hexokinase activity
Intracellular glucose concentration was measured using the Amplex
Red Glucose/Glucose Oxidase assay kit (Invitrogen) and intracellular
hexokinase activity was measured using Hexokinase colorimetric
assay kit Biovision (Milpitas, CA). All procedures were followed accord-
ing to the manufacturer's instructions. The resulting glucose and hexo-
kinase values were normalized to the total protein concentration of
the samples measured by Bradford's reagent.
2.4.7. Statistical analysis
All experiments were repeated three times with 3 mice per group
(N= 3; data from each group of mice was pooled). The statistical anal-
ysis was carried out by analysis of variance (ANOVA) followed by the
Bonferroni post-hoc correction for intergroup comparisons. Quantita-
tive data from Western blots as depicted by the relative intensity of
the bands were analyzed by performing a Student's t test. P b 0.05 was
considered statistically signiﬁcant.
3. Results
3.1. P2X7r protein expression in the NAFLD liver is modulated by CYP2E1-
mediated oxidative stress and adipokine leptin
We have shown previously that CYP2E1-mediated oxidative stress
increases hepatic leptin and P2X7r both at mRNA and protein levels
[23,29]. This observation was also elucidated by Ikejima K et al. where
CCl4, CYP2E1 substrate, administration increased leptin levels [24].Since leptin is shown previously to be aiding in stellate cell proliferation
and ﬁbrogenesis, we wanted to study novel downstreammechanisms of
leptin action and its crosstalk with P2X7r in the liver [38,39]. Results
showed that the immunoreactivity of P2X7r in the NAFLD liver that
was co-administered with the hepatoxin BDCM, a substrate of CYP2E1
showed a signiﬁcant increase as compared to NAFLD mice alone
(Fig. 1A and B) (P b 0.05). Mice treated with CYP2E1 inhibitor diallyl sul-
ﬁde (DAS) ormice thatwere deﬁcient in leptin (LepKO) showed a signif-
icant decrease in the P2X7r immunoreactivity (immunohistochemistry
on liver slices) when compared to NAFLD + BDCM group (Fig. 1A and
B) (P b 0.05). There was a signiﬁcant increase in the mRNA expression
of P2X7r in NAFLD + BDCM group as compared to NAFLD group alone
while administration of DAS or use of Leptin KO mice signiﬁcantly de-
creased P2X7r mRNA expression suggesting that the P2X7r protein
might be intrinsic to the diseased liver (Fig. 1C) (P b 0.05). NAFLD
group had signiﬁcant micro and macro vesicular steatosis while
NAFLD + BDCM group had higher macrovesicular ﬁbrosis when com-
pared to NAFLD group alone as shown by Oil Red-O stain (Suppl Fig. 4).
Interestingly P2X7r KO mice showed marked decrease in Oil Red O
stain when compared to NAFLD groups.
3.2. Leptin-induced P2X7r is required for stellate cell activation in progressive
liver injury of NAFLD mice
Leptin has been shown to aid in the proliferation of stellate cells [25,
40–42]. The stellate cells are crucial for the wound healing response in
the liver though it has been shown to be involved in ﬁbrotic pathology
of progressive NAFLD and development of hepatocellular carcinoma
[43]. On the other hand P2X7 receptor activation has been shown to
participate in NASH pathophysiology via the inﬂammosome formation
but detailed mechanisms are unclear [28,31]. To study the role of leptin
induced P2X7r activation in stellate cell proliferation in progressive
NAFLD following CYP2E1 mediated oxidative stress, immunohisto-
chemistry, Western blot analysis and mRNA expression of stellate cell
activation marker α-SMA were studied. Results showed that there
was a signiﬁcant increase in sinusoidal immunoreactivity of α- SMA in
NAFLD + BDCM group as compared to NAFLD group alone (Fig. 2A
and B) (P b 0.05). Use of leptin and P2X7r KO mice signiﬁcantly de-
creased the immunoreactivity of α-SMA in the liver slices (Fig. 2A and
B). NAFLD + BDCM group had a signiﬁcant increase (N6 fold) in α-
SMA mRNA expression as compared to NAFLD group alone while lack
of leptin or P2X7r had signiﬁcantly decreased expression of the α-
SMAmRNA (Fig. 2C) (P b 0.05).Western blot analysis ofα-SMA protein
in liver homogenates showed a signiﬁcant increase of the protein in
NAFLD + BDCM group as compared to NAFLD group alone while use
of liver homogenates from Leptin or P2X7r KO mice showed a signiﬁ-
cant decrease in the band reactivitywhenmeasuredby Image J software
(Fig. 2D and E) (P b 0.05).
3.3. Leptin-induced P2X7r modulates GLUT4 levels in murine NASH livers
Leptin has been extensively studied for its role in the energy homeo-
stasis and metabolism [44]. However, due to the higher levels of leptin
in obese subjects as well as in fatty liver disease, it is unclear when
and where leptin function is regulated especially in the liver [45]. Stel-
late cells acquire a proliferating phenotype in liver injury and require in-
creased glucose transport into the cells apart from rapid utilization of
glucose to meet its energy needs [19,46]. To show whether leptin in-
duced P2X7r modulates GLUT4, a principal glucose transporter in the
liver, mRNA expressions, protein levels and localization of GLUT4 were
studied. Results showed that GLUT4mRNA expressionwas signiﬁcantly
upregulated (N70 fold) in the liver of NAFLD + BDCM group as com-
pared to NAFLD alone (Fig. 3A) (P b 0.05) whereas use of P2X7r or Lep-
tin KO mice livers had signiﬁcantly decreased mRNA expressions of
GLUT4 (Fig. 3A) (P b 0.05). Protein levels of GLUT4 as shownbyWestern
blot showed a signiﬁcant increase in NAFLD + BDCM group as
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KO or P2X7r KOmice treated with BDCM showed a signiﬁcant decrease
in the protein levels of GLUT4 in the liver (Fig. 3B–E) (P b 0.05). Since
western analysis of GLUT4 protein in the liver could not help in the
identity of a particular cell type where the GLUT4 expression might be
the highest, we performed immunohistochemistry. Results showed
that GLUT4 induction was highest in the sinusoidal cells in the
NAFLD + BDCM group as compared to NAFLD group alone (Suppl
Fig. 1A and B) (P b 0.05) while leptin KO or P2X7r KO had a signiﬁcant
decrease in the GLUT4 staining in these cell types. Since activated stel-
late cells have been shown to utilize higher glucose primarily through
GLUT4, we studied the GLUT4 localization in activated stellate cells
[19]. Dual labeling immunohistochemistry (Red: GLUT4; Brown: α-
SMA), showed a markedly higher number of co-localizations of GLUT4
protein and stellate cell activation marker α-SMA (Fig. 3F) suggesting
that the activated stellate cells might have an increased expression
and levels of GLUT4 following oxidative stress injury in progressive
NAFLDmodel. Similar Glut4-α-SMA colocalizations were also observed
in humanNASH sampleswhen comparedwith human controls suggest-
ing a strong correlation with the studies in mouse model of NASH
(Suppl Fig. 2C–F). Glut4 protein levels also showed a signiﬁcant increase
in rat hepatic stellate cells when stimulated with a P2X7r agonist and
leptin (Suppl Fig. 3A) followed by a similar increase in P2X7r protein
in these cells (Suppl Fig. 3B).
3.4. Lack of leptin or P2X7r decreases phosphorylation of AKT in oxidative
stress induced liver injury in progressive NAFLD mice
The downstreampathways of leptin and P2X7r activation have been
shown to act through PI3/AKT pathway with subsequent phosphoryla-
tion of AKT [27,34]. Based on our previous results in this study, it was
important that we study AKT phosphorylation as a result of leptin in-
duction of P2X7r and subsequent activation of the purinergic receptor
isoform. Results showed that NAFLD + BDCM group had signiﬁcantly
higher levels of p-AKT protein as compared to NAFLD group alone
(Fig. 4A–D) (P b 0.05). Use of leptin KO mice or mice that were devoid
of P2X7r showed signiﬁcant decrease in the P-AKT protein levels as
measured by Western blot analysis (Fig. 4A–D) (P b 0.05). The results
suggested that the injured liver of NAFLD mice that had leptin induced
P2X7r induction and subsequent activation might modulate the func-
tions of the diseased liver via the AKT pathway and correlate well
with the downstream events of these molecules. However the sug-
gested data is premature at this point since mere estimation of pAKT
levels in the liver does not explain the relationship of leptin-induced
P2X7 activation and the corresponding signaling events. To show
conclusively that leptin-induced P2X7r signaling is mediated through
AKT phosphorylation in activated stellate cells, rat myoﬁbroblast 8B
cells were used. Results showed that co-incubation of cells with leptin
(100 ng/ml) signiﬁcantly increased AKT phosphorylation as compared
to medium only group (Fig. 4E.i and E.iii). Cells treated with P2X7r ago-
nist Bz-ATP (P7 Ag) also increased AKT phosphorylation signiﬁcantly
when compared to controls as shown by immunoﬂuorescence micros-
copy and morphometry (Fig. 4E.i, E.ii and F) (P b 0.05). The increase in
AKT phosphorylation was signiﬁcantly higher than the leptin treated
cells (Fig. 4E.iii and F) (P b 0.05). Use of AKT inhibitor signiﬁcantly de-
creased the ﬂuorescent intensity (Fig. 4E.v and E.vi), (the decrease
was more pronounced in the leptin + P2X7r agonist group than leptin
or P2X7r agonist treated alone) in cells treated with both leptin and
P2X7r agonist suggesting that P2X7r-mediated AKT phosphorylation isFig. 2. A (i–iv). Smooth muscle actin (α-SMA) immunoreactivity as shown by immunohistoche
NAFLDmice exposed to BDCM(NAFLD+BDCM), themice deﬁcient of P2X7r gene fedwith high
fat diet and exposed to BDCM(LepKO). Imageswere taken at 20×magniﬁcation. B.Morphomet
were plotted on Y-axis) in NAFLD, NAFLD+ BDCM, P2X7r KO and Lep KO groups of mice (*P b
and Lep KO groups of mice as assessed by quantitative real time PCR, the expressions were no
NAFLD (*P b 0.05). D.Western blot analysis ofα-SMA protein levels. Lanes 1–4 represent NAFLD
in NAFLD, NAFLD + BDCM, Lep KO and P2X7r KO groups of mice, data was normalized againsdownstream of leptin. Use of P2X7r antagonist signiﬁcantly decreased
the AKT phosphorylation induced by leptin (Fig. 4E.vii and F). Use of
conditioned medium increased AKT phosphorylation (Fig. 4E.viii and
E.ix) while AKT inhibitor signiﬁcantly decreased it. The above results
suggested that P2X7r mediated phosphorylation of AKT was
(a) downstream of leptin and (b) was the principal driver of AKT phos-
phorylation since use of the agonist attenuated the phosphorylation
completely. However leptin-induced AKT phosphorylation is not ruled
out in these cells and it is unclear at this point whether there is any par-
allel role leptin-induced AKT phosphorylation.
Western blot analysis of phosphorylated AKT showed similar results
as shown in Fig. 4G and 4H.
3.5. P2X7r activation and subsequent AKT pathway modulates GLUT4
induction and translocation in stellate cells
To study the role of P2X7r-mediated signaling and the AKT pathway
in GLUT4 induction and translocation to the membrane, a transformed
rat stellate cell line was used. GLUT4 translocation has been shown to
be a major event in glucose transport across the membrane and is key
to increased stellate cell proliferation [19]. Cells incubated with leptin
were later ﬁxed and immunoreactivity to GLUT4 was analyzed by im-
munoﬂuorescence microscopy. Results showed that cells treated with
leptin (Fig. 5A.v) or P2X7 agonist (Fig. 5A.ii) had a signiﬁcant increase
in both the cytoplasmic and membrane localizations of GLUT4 as com-
pared to untreated control (Fig. 5A.i) cells. Interestingly, cells that
were incubated with both leptin and P2X7r agonist had a marked in-
crease in both localization of GLUT4 in the cell membrane as well as
strong protein levels in the cytoplasm as compared to either leptin
alone or P2X7r agonist treated cells. The data suggested a strong syner-
gistic effect on GLUT4 (Fig. 5A.vi) localization and protein induction.
Treatment of leptin-primed cells with P2X7r antagonist completely ab-
rogated the GLUT4 induction and translocation (Fig. 5A.iv and A.vi). A
parallel use of AKT inhibitorwith P2X7 agonist treated cells orwith con-
ditioned medium markedly decreased Glut4 protein and localization
suggesting P2X7r and AKT phosphorylation mediated GLUT4 transloca-
tion and induction were downstream of leptin (Fig. 5A.iv and A.ix). To
prove that the cellular microenvironment in diseased liver cross talks
with each other in the form of paracrine fashion and inﬂuences stellate
cell GLUT4 induction and translocation, cellswere incubatedwith a con-
ditioned medium that was generated by treating hepatocytes with
BDCM. Results showed that cells treated with conditioned medium
had marked increase in GLUT4 protein and its localization in the mem-
brane as compared to medium controls (Fig. 5A.viii) whereas, co-
incubation with AKT inhibitor markedly decreased the ﬂuorescent in-
tensity (Fig. 5A.ix), suggesting that hepatocyte-stellate cell crosstalk
might be a signiﬁcant event that inﬂuences P2X7r mediation of GLUT4
induction and translocation to the membrane.
3.6. P2X7r activation leads to increased intracellular glucose and hexokinase
activity in stellate cells
The fate of hepatic stellate cells in liver injury involves a crucial reg-
ulation of metabolism in these cells [47,48]. The trans-differentiation of
stellate cells from a quiescent state to a highly proliferative state re-
quires rapid glucose uptake and possibly a higher utilization of the glu-
cose stores for enhanced glycolysis [47]. To show that P2X7r mediated
GLUT4 induction and translocation regulated intracellular glucose levels
by increasing glucose uptake, concentrations of stellate cell glucosemistry in liver slices frommice fed with high-fat diet (60% kcal fat) as a model of NAFLD,
-fat diet and exposed to BDCM(P2X7r KO) andmice deﬁcient of leptin gene fedwith high-
ric analysis ofα-SMA immunoreactivity (mean data from three separatemicroscopicﬁelds
0.05). C. mRNA expressions ofα-SMA in liver tissue of NAFLD, NAFLD+ BDCM, P2X7r KO
rmalized with 18S and compared to the NAFLD group and represented as fold changes to
, NAFLD+BDCM, Lep KO and P2X7r KO. E. Band quantiﬁcation of theα-SMA immunoblot
t β-actin (*P b 0.05).
Fig. 3.A.mRNA expressions of Glucose transporter 4 (GLUT4) in liver tissue of NAFLD, NAFLD+BDCM, P2X7r KO and Lep KO groups ofmice as assessed by quantitative real time PCR, the
expressionswere normalizedwith internal control (18S) and compared to the NAFLD group and represented as fold changes to NAFLD (*P b 0.05). B.Western blot analysis of GLUT4 pro-
tein levels. Lanes 1–3 represent NAFLD, NAFLD+BDCMand Lep KO respectively. C: Band quantiﬁcation of the GLUT4 immunoblot in NAFLD, NAFLD+BDCM, Lep KO groups ofmice, data
was normalized against β-actin (*P b 0.05). D. Western blot analysis of GLUT4 protein levels in liver homogenate of NAFLD, NAFLD + BDCM and P2X7r KO respectively. E. Band quanti-
ﬁcation of theGLUT4 immunoblot inNAFLD, NAFLD+BDCM, P2X7rKOgroups ofmice, datawas normalized againstβ-actin (*P b 0.05). F (i-iv). Co-localization of GLUT4 (red) andα-SMA
(brown) by immunohistochemistry in liver slices frommice fed with high-fat diet (60% kcal fat) as a model of NAFLD, NAFLD mice exposed to BDCM (NAFLD+ BDCM), P2X7r knockout
mice fed with high-fat diet and exposed to BDCM (P2X7r KO) and leptin knockout mice fed with high-fat diet and exposed to BDCM (Lep KO). Images were taken at 20× magniﬁcation.
(v) 60× oil magniﬁcation image of NAFLD + BDCM group to represent co-localization events of GLUT4 (red) and α-SMA (brown). The events were marked with black solid arrow.
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agonist, and with leptin signiﬁcantly raised intracellular glucose levels
as compared to untreated cells and compared to leptin alone (Fig. 6A)
(Left and Right Panels) (P b 0.05). Administration of P2X7r antagonist
signiﬁcantly decreased the intracellular glucose levels (Fig. 6A) (P b
0.05). Since hexokinase levels remain high and its activity is key to glu-
cose utilization in stellate cells for glycolytic pathway, as evidenced in
situations where the stellate cell acquires a myoﬁbroblastic lineage,
we studied the fate of the increased intracellular glucose by measuring
the activity of hexokinase (HK) [19]. Results showed that co-
incubation of cells with P2X7 agonist or leptin signiﬁcantly upregulated
the activity of HK by 45–50% (Fig. 6B) (P b 0.05), whereas administra-
tion of the P2X7r antagonist signiﬁcantly decreased the HK activity
(Fig. 6B) (P b 0.05). The results suggested that leptin and p2X7r modu-
lated glucose metabolic fate in stellate cells possibly by its actions on
GLUT4 induction and translocation and the two events were closely
correlated.
4. Discussion
The present study shows a novel role of P2X7r in modulating GLUT4
induction and translocation in hepatic stellate cells. The study which
uses an experimental murine model of NAFLD with concomitant meta-
bolic oxidative stress as a “second hit” outlines a mechanistic investiga-
tion of the role of leptin, P2X7r induction, GLUT4 translocation and
ﬁnally higher intracellular glucose in hepatic stellate cells. The study is
signiﬁcant since it identiﬁes a new mediator for stellate cell activation
and proliferation crucial for NASH progression.
We and others have shown previously that metabolic oxidative
stress increases systemic and hepatic leptin levels over and above the
levels found in obesity [23,24]. Increased leptin can perform an array
of functions or dysfunctions that affect a myriad of pathways causing
dysregulation in immune, endothelial and metabolic functions in
NASH [38]. Leptin has been shown to cause increased GLUT4 transloca-
tion in stellate cells apart from its more established role of causing in-
creased stellate cell proliferation but the downstream mechanisms in
metabolic alterations in these cells have been unclear [19]. Since there
are several literature reports including reports from our laboratory
that suggest the strong involvement of P2X7r in inﬂammatory and cell
fate regulations in the hepatocellular microenvironment, we argued
that circulating leptin might induce P2X7r and leptin-mediated P2X7r
activation in NASH might have a role in the metabolic dysregulation in
the liver especially in stellate cells [28,29]. Interestingly Dranoff J.A.
et al reported a strong involvement of P2Y receptor subtypes in activat-
ed stellate cells [49]. The present study did not explore the role of the
P2Y receptors in NASH development due to our earlier observations
that P2X7rwas crucial for NADPH oxidase induced reactive oxygen spe-
cies generation, autophagy and altered pathogenesis in NASH. We are
not aware of any studies that link P2Y receptors with NADPH oxidase
activation in vivo. However it is possible that signiﬁcant crosstalk may
exist among different P2 receptors owing to their activation by nucleo-
sides. Our data of attenuated P2X7r protein levels in leptin knockout
mice show the strong role of leptin in inducing these receptors in the
NASH liver (Fig. 1B and C; N7 fold decrease in protein). However caution
needs to be exerted in interpretation of this particular data since the
current study does not show byway of leptin supplementation in leptin
KOmice, whether there is a strong upregulation of P2X7r in these livers.
Our data of decreased P2X7r in DAS treated livers also correlates well
with the argument that oxidative stress, increased leptin and P2X7r in-
duction and/or activation might be strongly associated (Fig. 1).
We have shown previously that P2X7r KO mice are protected from
NASH associated ﬁbrosis [29]. In this study P2X7r knockout mice also
had signiﬁcantly decreased stellate cell activation as was indicated by
decreased immunoreactivity of α-SMA in NASH livers (Fig. 2). Stellate
cell transdifferentiation froma quiescent stage to amoremyoﬁbroblastic
lineage followed by proliferation is a signiﬁcant event in NASH [47,50].Studies have shown that the altered phenotype of stellate cells due to
liver injury causes a signiﬁcant alteration of its metabolic machinery
which includes increased glucose utilization and a preferable use of the
glycolyticmachinery even in aerobic circumstances [47]. The abovemet-
abolic pattern requires GLUT4 translocation to the membrane for
transporting increased glucose into the cell [19]. Leptin has been
shown to be involved in the process of translocation of GLUT4 to the
membrane but we are not aware of any studies that also reported its in-
duction by leptin or its downstream mediators [19]. Our study shows
that leptin-induced P2X7r was required for induction of GLUT4 in the
liver as shown by qRTPCR, Western blot and IHC analysis since both lep-
tin KO mice and P2X7r KO mice had decreased GLUT4 with P2X7r KO
showing a more pronounced depletion of the GLUT4 immunoreactive
band (Fig. 3E). Interestingly P2X7r KO mice barely expressed GLUT4
mRNA suggesting a strong transcriptional regulation of the GLUT4 pro-
tein by P2X7r in the injured liver (Fig. 3A). GLUT2 and GLUT4 are cellular
glucose transporters found in the liver probably in every cell type [51,
52]. Some studies suggest that insulin and insulin-like growth factor-1
aremitogenic for Hepatic Stellate Cells (HSC's) in spite of the fact that in-
sulin resistance is a common etiology in NASH [53–56]. GLUT4 has been
shown to be insulin responsive in hepatocytes and stellate cells and is
tightly regulated primarily by activated PI3K [19,51]. As a response
from insulin signaling, GLUT4 is rapidly translocated to the cell mem-
brane to allow more glucose inﬂux [27,57]. The high glucose then stim-
ulates increased consumption in cells undergoing proliferation or that
are in need for higher metabolic activity [58]. Stellate cells, due to their
highermetabolic activity in injured liver are unique since NASH has doc-
umented insulin and leptin resistance [13]. It is unclear how the stellate
cells still respond to insulin and leptin. To prove that activated stellate
cells and not any other cell types express higher GLUT4 in NASH liver,
we conducted immunohistochemistry of GLUT4 (Suppl Fig. 1) (Fig. 3F).
Firstly, we found higher GLUT4 in sinusoidal cells and secondly we ob-
served co-localization of GLUT4 and α-SMA in the liver slices. The
same results were obtained with human liver slices where NASH livers
showed a marked increase in P2X7r (Suppl Fig. 2B). Importantly, Lep
KO or P2X7r KO mice had signiﬁcantly lower GLUT4 in stellate cells
(Fig. 3F). Based on these observations we argued that owing to the im-
portance of stellate cells in an injured liver, primarily for wound healing
response, there may be parallel (Insulin based-already known) and/or
leptin-linked P2X7r-mediated signaling pathway that help in maintain-
ing their high metabolic activity in NASH. The higher metabolic activity
may initiate more glucose inﬂux into these cells primarily by increased
GLUT4 induction and translocation. Firstly, to strengthen our argument
for an overt role of AKT pathway downstream of leptin-P2X7r axis we
performed in vitro experiments in rat stellate cells. Our data of attenua-
tion of AKT phosphorylation by the co-incubationwith P2X7r antagonist
in cells stimulated with leptin showed that P2X7r was central to leptin-
induced AKT phosphorylation (Fig. 4E and F). Further conﬁrmation of
the role of P2X7r induced GLUT4 induction and translocation in stellate
cells were achieved following in vitro experiments in stellate cells
and immunoﬂuorescence microscopy. Results showed that P2X7r
agonist + leptin had amarked increase in both protein levels andmem-
brane localization of GLUT4 while use of P2X7r antagonist abrogated it
(Fig. 5A.vii). Incubation with a hepatocyte derived conditioned medium
also signiﬁcantly increased induction and translocation of GLUT4, while
use of AKT inhibitor attenuated both of these functions. It is worthmen-
tioning that P2X7r has been shown to be activated by ATP released from
necrosed hepatocytes following CYP2E1 mediated oxidative stress [10].
The conditioned medium used in this study was also generated in the
same method where BDCM was used to be a substrate of CYP2E1 in
place of CCl4. It is justiﬁable to assume that the conditioned medium is
a good example of cellular microenvironment in NASH where necrosed
hepatocytes can activate P2X7r on stellate cells and cause their metabol-
ic alterations, increased responsiveness to higher GLUT4 and stellate cell
proliferation via AKT pathway. Finally, we also showed that P2X7r-
mediated higher GLUT4 protein and translocation resulted in higher
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increased glucose consumption only to be attenuated by use of
P2X7r antagonist and AKT inhibitor. Studies have shown that stellatecell proliferation requires higher glucose consumption and increased
hexokinase (HK) activity which creates a gradient that allows more
glucose to be brought into the cell [59]. Our results of increased HK
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indication of leptin–P2X7r axis in modulating stellate cell response
in NASH thoughwe have no direct evidence to prove this mechanism
in vivo. Finally, our results suggested that though insulin resistance
is rampant in NASH, stellate cells are responsive to leptin-induced
P2X7r-mediated glucose inﬂux primarily through induction and
translocation of GLUT4. Mechanistically, the induction and translo-
cation might be mediated by AKT phosphorylation initiated by
P2X7r (Fig. 7). However, doubts still remain whether the AKT phos-
phorylation induced by insulin signaling acts in parallel to P2X7r or
they act in concert and these two mediators are linked. Another lim-
itation in this study is the mechanism of leptin-induced P2X7r ex-
pression or activation. Interestingly our results show that leptin
knockout mice have a signiﬁcant decrease in P2X7r induction, a
sign of a direct inﬂuence of leptin signaling on P2X7r induction. ItFig. 4. A.Western blot analysis of p-AKT protein levels in liver homogenate of mice fed with hig
mice fedwith high-fat diet and exposed to BDCM(LepKO) respectively. B. Band quantiﬁcation p
against Total AKT (*P b 0.05). C. Western blot analysis of p-AKT protein in liver homogenate of
immunoblot in NAFLD, NAFLD+BDCM, P2X7r KO groups ofmice, data was normalized against
stellate cells cultured in high glucoseDMEMmediawith 10% FBS (Med ctrl) and treatedwith P2
(Lep + P7 Ag), leptin + AKT inhibitor (Lep + AKTi) and leptin + P2X7r agonist + AKT inhibi
media (CM) and hepatocyte conditioned media + AKT inhibitor (CM+ AKTi). Images were ta
data from three separate microscopic ﬁelds were plotted on Y-axis) in Med Ctrl, P7 Ag, Lep, Lep
0.05). G.Western blot analysis of p-AKT protein levels in 8B cell lysate of Med Ctrl, P7Ag, P7An,
immunoblot in Med Ctrl, P7Ag, P7An, AKTi, Lep, Lep + P7Ag, Lep + P7An and Lep + AKTi gromay be possible that leptin-induced NADPH oxidase activation and
subsequent release of reactive oxygen species may be responsible
for P2X7 induction, a hypothesis that needs further exploration.
The hypothesis is strengthened by the fact that in vitro experiments
suggested a parallel paracrine signaling inﬂuences Glut4 induction,
an event that may see the involvement of oxidative stress or cell
death signals like HMGB1 or extracellular ATP. Future studies may
focus on a P2X7r dependent stellate cell circuit that can be pharma-
cologically manipulated to potentiate insulin resistance in NAFLD/
NASH patients.
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Fig. 7.A pictorial representation of themolecular process in P2X7r-mediated Glut4 function inNASH hepatic stellate cells. BDCM (green rectangle) ismetabolized by CYP2E1 (sky blue) in
hepatocytes to produce oxidative stress, release of leptin andhepatocyte necrosis leading to release of ATP (purple circle). Leptin and the extracellular ATP then binds the stellate cell P2X7r
leading to the activation of the PI3/AKT pathway. The PI3/AKT pathway leads to increased Glut4 expression, protein levels and probable translocation to the membrane. This results in
increased glucose sequestration inside the stellate cell and rapid glucose utilization.
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